AB-FUBINACA
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | covered under the Federal Analogue Act in the United States and under similar bills in other countries |
| Identifiers | |
| CAS number | 1185282-01-2  |
| ATC code | ? |
| PubChem | CID 58124325 |
| Chemical data | |
| Formula | C20H21FN4O2 |
| Mol. mass | 368.16 g/mol |
|
|
AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9nM at CB1 and 23.2nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication,[1] but was never pursued for human use. Subsequently in 2012, this compound was discovered as an ingredient in synthetic cannabis blends in Japan,[2] along with a related compound AB-PINACA which had not previously been reported.
See also [edit]
References [edit]
- ^ Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106982
- ^ Uchiyama, N.; Matsuda, S.; Wakana, D.; Kikura-Hanajiri, R.; Goda, Y. (2012). "New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products". Forensic Toxicology 31: 93. doi:10.1007/s11419-012-0171-4.
 |
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
